Delivery Order SPE2DB24D2101-SPE2DB25FKPMQ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,101.10 to AmerisourceBergen Drug Corp on July 24, 2025, for 12,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, carrying an ultimate completion date of July 25, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply contract. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for 36,000 units of Creon DR 100s capsules, a pancreatic enzyme replacement medication. This firm fixed-price delivery order, valued at $11,775.31, represents a competitively awarded contract with an ultimate completion date of August 29, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside designation applied to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count packaging, valued at $2,254.12. This is a firm fixed-price delivery order with no set-aside designation, issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Creon DR 36,000 unit capsules in units of 100, with a contract ceiling value of $2,335.13 and an ultimate completion date of July 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $5,569.72. This competitive delivery order, structured as a firm fixed-price contract with no set-aside designation, will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. The award represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of 12,000 unit capsules of Creon DR 100s, with a ceiling value of $3,797.77. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 25, 2025, and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, demonstrating AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of 36,000 units of Creon DR 100s capsules, valued at $6,150.38. This competitively awarded, firm fixed-price delivery order is set to be completed by July 30, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Creon DR 24,000 unit capsules (100 count) with a ceiling value of $2,262.52 and an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of 24,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, with a contract value of $9,718.75. The order was competitively awarded without set-aside designation and is scheduled for completion by August 20, 2025. Performance will be executed from the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order operates under a firm...
- The Defense Logistics Agency awarded a $21,057.57 delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 11, 2025. AmerisourceBergen will perform this delivery order from its corporate headquarters in Conshohocken, Pennsylvania, where the company operates as a major...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKPMQDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Creon (pancrelipase) capsules, 36,000 units in 100-count bottles, with a ceiling value of $2,424.24 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of September 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical supply requirements. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The parent IDC enables AmerisourceBergen to supply an extensive portfolio of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen has demonstrated capability across multiple therapeutic domains and maintains significant competitive positioning within the DLA's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 9/12/25 |